Nelitolimod

Phase 1Small molecule

NNorthwell Health

Nelitolimod is one of 10 small molecule programs targeting Liver Metastases. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver MetastasesRecruiting

Liver MetastasesPhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Liver Metastases

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 2

9 2

Avastin

Roche

Phase 2

8 3

Camptosar

Pfizer

Phase 2

2 4

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

3 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 2

2 6

5-Fluorouracil

Merck & Co.

Phase 2

1 7

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 8

Anti-CEA CAR-T Cells

SSorrento Therapeutics, Inc.

Phase 1

4 9

Definity

LLantheus Medical Imaging

Preclinical

1 10

Nelitolimod

NNorthwell Health

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Liver Metastases

NCT07172282

Clinical

Trials by Indication[1]

Liver Metastases1 trial

INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

Recruiting·NNorthwell Health·Phase 1·NCT07172282·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nelitolimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nelitolimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nelitolimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwell Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNorthwell Health

Nelitolimod

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Liver Metastases1 trial

References

Drug Info

Quick Facts

Related News